What This Bill Does · Plain English
Summary · Congress.gov
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation. The bill's changes apply retroactively.
Top Winners · Companies that benefit if HR.1492 passes
80% confidence
Delays negotiation on small-molecule portfolio; Trump holds PFE $15,001-$50,000 per get_executive_branch_exposure; $33B federal contracts (HHS, DoD, VA) per get_government_precedent
75% confidence
Trump holds LLY $100,001-$250,000 per get_executive_branch_exposure; $3.3B federal contracts (DoD, VA) per get_government_precedent; 43 congressional buys per get_sector_political_positioning
70% confidence
86 congressional buys (e.g., Cisneros D, Foxx R) vs 76 sells per get_sector_political_positioning; Trump holds JNJ $50,001-$100,000 per get_executive_branch_exposure
Top winners identified by GovGreed LLM analysis.
Frequently Asked Questions
Did HR.1492 pass?
HR.1492 is still alive. Current stage: COMMITTEE. Pass likelihood: 44%.
What does HR.1492 do?
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug produ…
Who sponsored HR.1492?
HR.1492 was sponsored by Gregory F. Murphy (R-North Carolina).
What companies benefit from HR.1492?
Top public companies expected to benefit: PFE, LLY, JNJ. Affected sectors: healthcare, pharma.
Full Bill Text
119 HR 1492 IH: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. U.S. House of Representatives 2025-02-21 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 119th CONGRESS 1st Session H. R. 1492 IN THE HOUSE OF REPRESENTATIVES February 21, 2025 Mr. Murphy (for himself, Mr. Davis of North Carolina , and Mr. Hudson ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. 1. Equalizing the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program (a) In general Section 1192(e)(1)(A)(ii) of the Social Security Act ( 42 U.S.C. 1320f–1(e)(1)(A)(ii) ) is amended by striking 7 years and inserting 11 years . (b) Effective date The amendment made by subsection (a) shall take effect as if included in the enactment of Public Law 117–169 .
Loading intelligence layer…